Loading stock data…
STRO
$38.39+2.80 (+7.87%)
Sutro Biopharma, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sutro Biopharma, Inc. in the Healthcare sector is trading at $38.39. The stock is currently near its 52-week high of $39.10, remaining 167.2% above its 200-day moving average. Technical signals show overbought RSI of 78 and bullish MACD crossover, explaining why STRO maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 78) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$38.39
Potential Upside
5%
Whystock Fair Value$40.31
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$35.73-6.9%
Range$9.00 – $55.00
Fundamentals
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conju...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$588.63M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
157.56%
Volume
Today's trading volume
270,630
Recent News
Citizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead Program
Sutro Biopharma, Inc. (NASDAQ:STRO) is one of the best performing small cap stocks so far in 2026. Citizens lifted the price target on Sutro Biopharma, Inc. (NASDAQ:STRO) to $41 from $35 on April 23, reaffirming an Outperform rating on the shares. The firm told investors in a research note that the recent AACR presentations highlighted […]
Meta downgraded, Qualcomm upgraded: Wall Street's top analyst calls
Meta downgraded, Qualcomm upgraded: Wall Street's top analyst calls
Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now
Sutro Biopharma Inc. (NASDAQ:STRO) is one of the tiny stocks that are on fire right now. On March 23, Sutro Biopharma reported its full-year 2025 financial results, highlighting a strengthened balance sheet and significant clinical milestones for its antibody-drug conjugate/ADC platform. The company ended 2025 with $141.4 million in cash and marketable securities, which, when […]
Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Arm downgraded, Arista Networks upgraded: Wall Street's top analyst calls
Arm downgraded, Arista Networks upgraded: Wall Street's top analyst calls